This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Advanced Cancer, Metastatic Cancer, Biliary Tract Carcinoma, Cholangiocarcinoma, Gall Bladder Carcinoma, Solid Tumor or Non-Hodgkin's Lymphoma
and you are
over 20
years old
Phase
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer.

Provided treatments

  • Drug: Merestinib
  • Drug: Cisplatin
  • Drug: Gemcitabine
Tris trial is registered with FDA with number: NCT03027284. The sponsor of the trial is Eli Lilly and Company and it is looking for 18 volunteers for the current phase.
Official trial title:
A Phase I Study of Merestinib Monotherapy or in Combination With Other Anti-Cancer Agents in Japanese Patients With Advanced and/or Metastatic Cancer